How do I… manage the platelet transfusion–refractory patient?
JE Juskewitch, AP Norgan, SR De Goey… - …, 2017 - Wiley Online Library
JE Juskewitch, AP Norgan, SR De Goey, PM Duellman, LL Wakefield, MJ Gandhi…
Transfusion, 2017•Wiley Online LibraryBACKGROUND Platelet transfusion–refractoriness is a challenging and expensive clinical
scenario seen most often in patients with hematologic malignancies. Although the majority of
platelet transfusion–refractory cases are due to nonimmune causes, a significant minority
are caused by alloimmunization against Class I human leukocyte antigens (HLAs) or human
platelet antigens (HPAs). Such platelet transfusion–refractory patients can be effectively
managed with appropriate antigen‐negative products. STUDY DESIGN AND METHODS …
scenario seen most often in patients with hematologic malignancies. Although the majority of
platelet transfusion–refractory cases are due to nonimmune causes, a significant minority
are caused by alloimmunization against Class I human leukocyte antigens (HLAs) or human
platelet antigens (HPAs). Such platelet transfusion–refractory patients can be effectively
managed with appropriate antigen‐negative products. STUDY DESIGN AND METHODS …
BACKGROUND
Platelet transfusion–refractoriness is a challenging and expensive clinical scenario seen most often in patients with hematologic malignancies. Although the majority of platelet transfusion–refractory cases are due to nonimmune causes, a significant minority are caused by alloimmunization against Class I human leukocyte antigens (HLAs) or human platelet antigens (HPAs). Such platelet transfusion–refractory patients can be effectively managed with appropriate antigen‐negative products.
STUDY DESIGN AND METHODS
Our institution has developed a diagnostic and management algorithm for the platelet transfusion–refractory patient with an early focus on identifying those cases caused by immune‐mediated factors. Using physical platelet cross‐matches to initially classify platelet transfusion–refractory patients as immune‐mediated or not, cross‐match–compatible inventory is then provided to immune‐mediated patients, whereas subsequent HLA (with or without HPA) testing is performed.
RESULTS
Our blood donor program performs Class I HLA typing of all repeat platelet donors to facilitate the identification of antigen‐negative platelet units (virtual cross‐matching) as well as the recruitment of HLA‐matched donors. The platelet transfusion–refractoriness algorithm realizes an initial net cost savings once two apheresis platelets are saved from use for each newly identified, immune‐mediated platelet transfusion–refractory patient.
CONCLUSION
An algorithm utilizing physical platelet cross‐matches, Class I HLA and HPA antibody testing, and upfront Class I HLA typing of platelet donors leads to overall resource savings and improved clinical management for platelet transfusion–refractory patients.
Wiley Online Library